# Beacon Biosignals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beacon-biosignals

- Industry: Software
- Headquarters: Boston, US
- Website: www.beacon.bio
- Total disclosed funding: $124M
- Latest round: Series B (Apr 6, 2026)
- Investors on record: 15

## About

Beacon Biosignals, Inc. is a Boston-based company specializing in AI-driven neurotechnology, focused on improving the understanding and treatment of neurological and psychiatric disorders through innovative EEG data capture solutions.Beacon Biosignals, Inc. was founded in 2019 by co-founder Jacob Donoghue and Jarrett Revels, and headquartered in Boston, US. The company specializes in neurotechnology that leverages AI to enhance the treatment of neurological and psychiatric disorders. In April 2026, Beacon Biosignals, Inc. raised USD 11 million in series B funding from JSL Health Capital, Palo Santo Venture Fund, Kicker Ventures, and Samsung NEXT Ventures. The round was part of a larger USD 114 million in series B funding. Beacon Biosignals specializes in AI-powered neurotechnology aimed at enhancing the understanding and treatment of neurological and psychiatric disorders. Their core offerings include an FDA-cleared headband that captures high-fidelity electroencephalography (EEG) data both at home and in clinical settings. This technology enables the collection and analysis of sleep data to identify novel biomarkers, assess treatment effects, and stratify patient populations effectively. Beacon’s services cater to a broad range of indications, addressing psychiatric disorders like major depressive disorder, schizophrenia, and bipolar disorder, as well as primary and secondary sleep disorders. The company's technology is utilized by clinical development teams in North America and Europe, collaborating with leading pharmaceutical companies to facilitate clinical trials and drug development processes.The revenue model of Beacon Biosignals primarily revolves around B2B transactions, focusing on partnerships with pharmaceutical companies and clinical research organizations. Clients engage with Beacon to access its platform and services, which include analytics software and support from the Clinical Study Operations and Scientific Services teams. The company may employ a subscription-based pricing structure for ongoing access to its technology and data analytics capabilities. Additionally, revenue could be generated through specific project-based agreements, where clients pay for tailored services related to clinical trial management and reporting. Such transactions involve detailed agreements on data utilization and analysis, enabling clients to derive meaningful insights from the EEG data collected during their studies.

## Funding rounds

- Series B, Apr 6, 2026, $11M — Samsung NEXT Ventures, JSL Health Capital, Kicker Ventures, Palo Santo Venture Fund
- Series B, Nov 12, 2025, $86M — General Catalyst Partners, GV, Casdin Capital, Indicator Ventures, Iaso Ventures, Logos Capital, Innoviva, Inc., Catalio Capital Management, Nexus NeuroTech Ventures, Takeda Digital Ventures, S32
- Series A, Jul 11, 2023 — General Catalyst Partners
- Series A, Nov 8, 2021, $27M — General Catalyst Partners, Casdin Capital

## Investors

- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Indicator Ventures (https://capitalatlas.ai/funds/indicator-ventures) — Series B
- Iaso Ventures (https://capitalatlas.ai/funds/iaso-ventures) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Innoviva, Inc. — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Nexus NeuroTech Ventures (https://capitalatlas.ai/funds/nexus-neurotech-ventures) — Series B
- Takeda Digital Ventures (https://capitalatlas.ai/funds/takeda-digital-ventures) — Series B
- S32 — Series B
- Samsung NEXT Ventures (https://capitalatlas.ai/funds/samsung-next-ventures) — Series B
- JSL Health Capital (https://capitalatlas.ai/funds/jsl-health-capital) — Series B
- Kicker Ventures (https://capitalatlas.ai/funds/kicker-ventures) — Series B
- Palo Santo Venture Fund (https://capitalatlas.ai/funds/palo-santo-venture-fund) — Series B